Parmax Pharma Ltd announced an open offer to acquire 23.46 lakh shares at ₹42.80 each, representing 26% of its equity. The company, however, has a history of financial losses and regulatory non-compliance.
Parmax Pharma Ltd Announces Open Offer Amidst Financial and Regulatory Challenges
Parmax Pharma Ltd is launching an open offer to acquire 23,46,250 shares, or 26% of its expanded equity, at ₹42.80 per share. This offer, valued at ₹10.04 crore, aims to facilitate a change in management control and support business expansion. ## What Just Happened An open offer for 23,46,250 shares at ₹42.80 each, totaling ₹10.04 crore, has been announced by Parmax Pharma Ltd. This follows a Share Purchase Agreement and a proposed preferential issue, leading to a change in management control. The offer represents 26% of the company's expanded equity. ## Why This Matters This open offer presents an exit opportunity for existing shareholders at a fixed price. However, the company has consistently reported losses, with the net loss widening to ₹4.16 crore in FY26 from ₹2.09 crore in FY25. Investors must weigh the offer against the company's financial performance and history of regulatory issues. ## The Backstory Parmax Pharma is involved in the research, manufacturing, and sale of APIs, bulk drugs, and specialty chemicals. The company has consistently incurred losses from FY2024 to FY2026. The proposed transaction involves acquiring substantial control by new Acquirers and Persons Acting in Concert (PACs). ## What Changes Now New management intends to focus on growing the API and drug intermediate manufacturing business. While there's no stated intention to delist, a change in control and management strategy is anticipated. The tendering period for the open offer is scheduled from July 30, 2026, to August 12, 2026. ## Risks to Watch Investors should be aware of past regulatory non-compliance, including penalties from BSE for delayed filings and failure to appoint a company secretary. Qualified audit reports have been issued for FY2024-25 and the June 2025 quarter. Governance concerns include a potential violation regarding a ₹0.40 crore mutual fund investment and past issues with board composition and filings. ## Peer Comparison (No verified peer comparison data available in the filing.) ## Context Metrics (Time-Bound) * **FY2026 Revenue:** ₹12.11 crore (Loss: ₹4.16 crore) * **FY2025 Revenue:** ₹28.20 crore (Loss: ₹2.09 crore) * **FY2024 Revenue:** ₹11.05 crore (Loss: ₹5.75 crore) ## What to Track Next Investors should monitor the company's compliance with minimum public shareholding norms post-acquisition, as the acquirers' combined holding could reach 94.34%. Consulting financial advisors before participating in the open offer is recommended.
